Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly has entered into two strategic collaborations to advance its oncology and metabolic disease portfolios124.
Lilly partnered with AdvanCell, an Australian radiopharmaceutical company, to develop targeted alpha therapies for cancer treatment135.
The collaboration with AdvanCell will leverage their proprietary Pb-212 production technology and radionuclide development infrastructure12.
Lilly also signed an agreement with OliX Pharmaceuticals, a South Korean biotech firm, to develop treatments for metabolic dysfunction-associated steatohepatitis (MASH) and other cardiometabolic diseases46.
The OliX deal centers on OLX75016, a small interfering RNA therapy targeting the MARC1 enzyme, currently in Phase I trials for MASH46.
Financial details of both collaborations were not fully disclosed, though OliX will receive an initial payment from Lilly to complete the Phase I trial of OLX7501668.
These partnerships align with Lilly's strategy to expand its presence in the radiopharmaceutical and MASH treatment spaces45.
Sources:
1. https://www.businesswire.com/news/home/20250210990350/en/AdvanCell-Enters-Into-Strategic-Collaboration-with-Lilly-to-Advance-Novel-Targeted-Alpha-Therapies-for-the-Treatment-of-Cancer
2. https://www.biospectrumasia.com/news/26/25558/australias-advancell-partners-with-lilly-to-develop-new-targeted-alpha-therapies-for-cancer-treatment.html
3. https://www.afp.com/en/infos/advancell-enters-strategic-collaboration-lilly-advance-novel-targeted-alpha-therapies
4. https://www.biospace.com/business/lilly-signs-back-to-back-deals-in-mash-cancer
5. https://pharmasource.global/content/biotech-news/advancell-expands-strategic-collaboration-with-eli-lilly-for-targeted-alpha-therapies/
6. https://markets.businessinsider.com/news/stocks/eli-lilly-enters-global-license-agreement-with-olix-for-olx75016-1034335326
8. https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Olix-US-Eli-Lilly-Sign-MASH-and-Cardiovascular-and-Metabolic-Disease-Treatment-License-Agreement-49010212/